title: PHARMAC has no cost-effectiveness threshold.
authors.forename: Scott
authors.initials: S
authors.lastname: Metcalfe
authors.forename: Alexander
authors.initials: A
authors.lastname: Rodgers
authors.forename: Rachel
authors.initials: R
authors.lastname: Werner
authors.forename: Carsten
authors.initials: C
authors.lastname: Schousboe
mesh_terms: D003362:Cost-Benefit Analysis; D005380:Financing, Government; D007356:Insurance, Pharmaceutical Services / Q000191:economics*; D009313:National Health Programs / Q000191:economics* / Q000458:organization & administration; D009520:New Zealand; D019057:Quality-Adjusted Life Years